<DOC>
	<DOCNO>NCT00664196</DOCNO>
	<brief_summary>This study test safety tolerability autologous anti-PSMA gene-modified T cell ( designer T cell ) hormone refractory prostate cancer .</brief_summary>
	<brief_title>Trial Anti-PSMA Designer T Cells Advanced Prostate Cancer After Non-Myeloablative Conditioning</brief_title>
	<detailed_description>The study create autologous gene-modified T cell prostate specific membrane antigen ( PSMA , unrelated PSA ) ( designer T cell ) ex vivo modification patient T cell . T cell collect leukopheresis , transport RWMC cGMP Cell Manipulation Core transduce retrovirus contain chimeric antigen receptor ( CAR ) express modified cell . This CAR link specificity antibody PSMA signal domain T cell redirect recognition T cell engage kill prostate cancer cell anywhere body . These administer dose 10^10 randomization either low moderate Interleukin 2 give CI ( continuous infusion ) one month follow T cell infusion . Subsequent subject receive 10^11 cell Interleukin 2 either low moderate dose , non randomized manner , depend upon outcome prior cohort . Prior T cell infusion , subject receive non-myeloablative ( NMA ) conditioning . This conditioning create `` space '' blood marrow engraftment infuse cell maintain high level anti-tumor effector T cell body . Each patient treat single dose T cell , without repeat dosing . Patients follow toxicity response pharmacokinetics-pharmacodynamics infused T cell . Patients on-study one-month T cell dose .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm diagnosis prostate cancer 2 . Elevated PSA 3 . Life expectancy &gt; 4 month 4 . Performance status 01 5 . ANC 1.0 6 . Platelets &gt; 100,000 7 . Hemoglobin &gt; 8.0 8 . Creatinine &lt; 1.5mg/dl 9 . Direct Bilirubin &lt; 1.5 mg/dl 10 . No evidence CHF , CAD , cardiac arrhythmia , Afib , A flutter , myocardial infarction . 11 . No serious , symptomatic obstructive emphysematous lung disease 12 . No asthma require IV medication last 12 month , serious lung disease associate dyspnea normal activity level , rest due cause , include cancer metastasis pleural effusion 13 . Patients must biopsy able tumor , willing undergo biopsy ( Group 3 ) 14 . Patient least 18 year age . 1 . Serious unstable renal , hepatic , pulmonary , cardiovascular , endocrine , rheumatologic allergic disease base history , labs physical exam 2 . Active clinical disease cause CMV , Hepatitis B , C , HIV , TB 3 . Cytotoxic and/or radiation therapy last 4 week prior entry 4 . Any concurrent malignancy 5 . Patient require systemic steroid 6 . Patient participate prior investigational therapy 7 . Patient prior exposure mouse antibody 8 . Patient irradiation whole pelvis &gt; 25 % marrow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>T cell</keyword>
	<keyword>Gene Transfer</keyword>
</DOC>